Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
R B Diasio, … , T L Beavers, J T Carpenter
R B Diasio, … , T L Beavers, J T Carpenter
Published January 1, 1988
Citation Information: J Clin Invest. 1988;81(1):47-51. https://doi.org/10.1172/JCI113308.
View: Text | PDF
Research Article Article has an altmetric score of 259

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

  • Text
  • PDF
Abstract

Severe neurotoxicity due to 5-fluorouracil (FUra) has previously been described in a patient with familial pyrimidinemia. We now report the biochemical basis for both the pyrimidinemia and neurotoxicity in a patient we have recently studied. After administration of a "test" dose of FUra (25 mg/m2, 600 microCi[6-3H]FUra by intravenous bolus) to a patient who had previously developed neurotoxicity after FUra, a markedly prolonged elimination half-life (159 min) was observed with no evidence of FUra catabolites in plasma or cerebrospinal fluid and with 89.7% of the administered dose being excreted into the urine as unchanged FUra. Using a sensitive assay for dihydropyrimidine dehydrogenase in peripheral blood mononuclear cells, we demonstrated complete deficiency of enzyme activity in the patient and partial deficiency of enzyme activity in her father and children consistent with an autosomal recessive pattern of inheritance. Patients who are deficient in this enzyme are likely to develop severe toxicity after FUra administration.

Authors

R B Diasio, T L Beavers, J T Carpenter

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1969 Total
Citations: 3 6 5 6 10 8 6 6 4 8 7 8 16 11 2 13 9 15 18 18 15 13 13 14 17 8 13 8 11 13 8 8 10 1 10 6 2 1 1 351
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (351)

Title and authors Publication Year
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)
Hanrath MA, Banken E, van den Wildenberg SA, van de Kerkhof D, Moes DJ, Boisdron-Celle M, van den Bosch BJ, Bax R, Bet PM, Maring JG, Creemers GJ, van Hellemond IE, Deenen MJ
Cancer Chemotherapy and Pharmacology 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK
Clinical Pharmacology and Therapeutics 2025
Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil
Fiebrich-Westra HB, Haroun C, van der Galiën R, den Besten-Bertholee D, Deenen MJ, Moes DJ, Bet PM, de Groot JW, Brohet RM, van Kuilenburg AB, Maring JG
JCO Precision Oncology 2025
Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.
Montella A, Cantalupo S, D'Alterio G, Damiano V, Iolascon A, Capasso M
2024
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review
Chan TH, Zhang JE, Pirmohamed M
British Journal of Cancer 2024
Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches
Lyrio RM, Rocha BR, Corrêa AL, Mascarenhas MG, Santos FL, Maia RD, Segundo LB, de Almeida PA, Moreira CM, Sassi RH
Frontiers in Nephrology 2024
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
Cheng Y, Teng Z, Zhang Y, Jin B, Zheng Z, Man L, Wang Z, Teng Y, Yu P, Shi J, Luo Y, Wang Y, Zhang J, Zhang H, Liu J, Chen H, Xiao J, Zhao L, Zhang L, Jiang Y, Chen Y, Zhang J, Wang C, Liu S, Qu J, Qu X, Liu Y
BMC Cancer 2024
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan HT, Emilescu RA, Iaciu CI, Orlov-Slavu CM, Olaru MC, Popa AM, Jinga M, Nitipir C, Schreiner OD, Ciobanu RC
Cancers 2024
Characterization of Reference Materials for DPYD: A GeT-RM Collaborative Project
Gaedigk A, Turner AJ, Moyer AM, Zubiaur P, Boone EC, Wang WY, Broeckel U, Kalman LV
The Journal of molecular diagnostics : JMD 2024
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.
Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O
Therapeutic advances in medical oncology 2023
DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation.
Wigle TJ, Medwid S, Ross C, Schwarz UI, Kim RB
Current oncology (Toronto, Ont.) 2023
3D Printed Pharmaceutical Systems for Personalized Treatment in Metabolic Syndrome.
Alqahtani AA, Ahmed MM, Mohammed AA, Ahmad J
Pharmaceutics 2023
DPYD Testing: Time to Put Patient Safety First.
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM
Journal of Clinical Oncology 2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicity.
Hertz DL, Lustberg MB, Sonis S
Supportive Care in Cancer 2023
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
Glewis S, Alexander M, Khabib MNH, Brennan A, Lazarakis S, Martin J, Tie J, Lingaratnam S, Michael M
British Journal of Cancer 2022
Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers.
Brazelton A, Yande S, Pope R, Johnson ML, Musher B, Trivedi MV
Annals of Gastroenterology 2022
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.
Diasio RB, Offer SM
Cancers 2022
Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis.
Laures N, Konecki C, Brugel M, Giffard AL, Abdelli N, Botsen D, Carlier C, Gozalo C, Feliu C, Slimano F, Djerada Z, Bouché O
Pharmaceutics 2022
Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door.
Donadio MDS, Carraro DM, Torrezan GT, de Mello CAL
ecancermedicalscience 2022
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays.
De Luca O, Salerno G, De Bernardini D, Torre MS, Simmaco M, Lionetto L, Gentile G, Borro M
International journal of molecular sciences 2022
A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma
N Kash, S Silapunt
Future Oncology 2021
Oncologic Emergency Medicine: Principles and Practice
KH Todd, CR Thomas, K Alagappan
2021
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
K Heinrich, DP Modest, I Ricard, LF von Weikersthal, T Decker, F Kaiser, U Graeven, J Uhlig, M Schenk, J Freiberg-Richter, B Peuser, C Denzlinger, C Giessen-Jung, A Stahler, M Michl, S Held, A Jung, T Kirchner, S Stintzing, V Heinemann
European Journal of Cancer 2021
Pharmacogenomic‐Guided Therapy in Colorectal Cancer
RB Diasio, F Innocenti, SM Offer
Clinical Pharmacology & Therapeutics 2021
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
TJ Wigle, BL Povitz, S Medwid, WA Teft, RM Legan, J Lenehan, S Nevison, V Panuganty, D Keller, J Mailloux, V Siebring, S Sarma, Y Choi, S Welch, E Winquist, UI Schwarz, RB Kim
Clinical and Translational Science 2021
The Interaction of Porcine Dihydropyrimidine Dehydrogenase with the Chemotherapy Sensitizer: 5-Ethynyluracil
DC Forouzesh, BA Beaupre, A Butrin, Z Wawrzak, D Liu, GR Moran
Biochemistry 2021
Mammalian dihydropyrimidine dehydrogenase
DC Forouzesh, GR Moran
Archives of Biochemistry and Biophysics 2021
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study
C Gallois, E Hafliger, E Auclin, A Perret, C Coutzac, A Turpin, A Pellat, V Randrian, D Basile, R Faroux, S Pernot, C Locher, V Hautefeuille, O Dubreuil, LJ Palmieri, M Dior, P Artru, J Taieb
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2021
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
P García-Alfonso, M Saiz-Rodríguez, R Mondéjar, J Salazar, D Páez, AM Borobia, MJ Safont, I García-García, R Colomer, X García-González, MJ Herrero, LA López-Fernández, F Abad-Santos
Clinical and Translational Oncology 2021
Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.
Ruiz-Bañobre J, Goel A
Advances in cancer research 2021
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients
N Matsumoto, Y Kubota, H Ishida, M Sekido, R Ohkuma, T Ishiguro, Y Hirasawa, H Ariizumi, T Tsunoda, T Ikusue, K Kobayashi, A Hisamatsu, H Toshima, K Shimada, K Fujita
Cancer Chemotherapy and Pharmacology 2020
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide
F Innocenti, SC Mills, H Sanoff, J Ciccolini, HJ Lenz, G Milano
2020
Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea
M Sakumura, T Ando, A Hosokawa, T Nakajima, I Motoo, H Mihara, A Ueda, S Kajiura, S Nanjo, H Fujinami, K Ogawa, I Yasuda
BMC Gastroenterology 2020
Adjuvant Chemotherapy for Stage III Colon Cancer
J Taieb, C Gallois
Cancers 2020
Comparison of 4 Screening Methods for Detecting Fluoropyrimidine Toxicity Risk: Identification of the Most Effective, Cost-Efficient Method to Save Lives
O Capitain, V Seegers, JP Metges, R Faroux, C Stampfli, M Ferec, TM Budnik, H Senellart, V Rossi, N Blouin, J Dauvé, M Campone
Dose-Response 2020
Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine
M Monti, D Barone, E Amadori, G Bartolini, S Ruscelli, GL Frassineti
Journal of Oncology Pharmacy Practice 2020
Toxic and Adverse Effects of Chemotherapy with 5-Fluoropyrimidine Drugs. Could Dihydropyrimidine Dehydrogenase Enzyme Screening Serve as a Prerequisite to Successful Chemotherapy?
VT Minchev
2020
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
B Wörmann, C Bokemeyer, T Burmeister, CH Köhne, M Schwab, D Arnold, JU Blohmer, M Borner, S Brucker, I Cascorbi, T Decker, M de Wit, A Dietz, H Einsele, W Eisterer, G Folprecht, W Hilbe, J Hoffmann, W Knauf, V Kunzmann, CR Largiadèr, S Lorenzen, D Lüftner, M Moehler, MM Nöthen, C Pox, A Reinacher-Schick, A Scharl, B Schlegelberger, T Seufferlein, M Sinn, M Stroth, I Tamm, L Trümper, M Wilhelm, E Wöll, RD Hofheinz
Oncology Research and Treatment 2020
Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research
L Ozgyin, A Horvath, Z Hevessy, BL Balint
Scientific Reports 2019
Hyperammonemia after capecitabine associated with occult impairment of the urea cycle
G Chu, J Salzman
Cancer Medicine 2019
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
TJ Wigle, EV Tsvetkova, SA Welch, RB Kim
Pharmaceutics 2019
Basal Cell Carcinoma: Advances in Treatment and Research
MR Migden, L Chen, S Silapunt
2019
Fluoropyrimidine-Associated Cardiotoxicity
J Kanduri, LA More, A Godishala, A Asnani
Cardiology Clinics 2019
Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs
V Sharma, SK Gupta, M Verma
Cancer Chemotherapy and Pharmacology 2019
5-fluorouracil and cardiotoxicity: a review
JD Sara, J Kaur, R Khodadadi, M Rehman, R Lobo, S Chakrabarti, J Herrmann, A Lerman, A Grothey
Therapeutic advances in medical oncology 2018
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
R Palmirotta, C Carella, E Silvestris, M Cives, SL Stucci, M Tucci, D Lovero, F Silvestris
Oncotarget 2018
Colorectal Cancer - Diagnosis, Screening and Management
J Chen
2018
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre
M Moloney, D Faulkner, E Link, D Rischin, B Solomon, AM Lim, JR Zalcberg, M Jefford, M Michael
Cancer Chemotherapy and Pharmacology 2018
A direct, sensitive and efficient method for determination of alpha-fluoro-beta-alanine in urine: Evaluating the influence of magnesium isoglycyrrhizinate on excretion in rat model
Z Wang, Y Yang, F Zhang, M Li, J Chen, H Man, W Jiang, R Zhang, S Gao, W Chen
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2018
Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer
SL Chan, AW Chan, F Mo, BB Ma, KC Wong, D Lam, FS Mok, AT Chan, T Mok, KC Chan
The oncologist 2018
Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo
L Patras, B Sylvester, L Luput, A Sesarman, E Licarete, A Porfire, D Muntean, DM Drotar, AD Rusu, AL Nagy, C Catoi, I Tomuta, L Vlase, M Banciu, M Achim
Cancer biology & therapy 2017
Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo
L Patras, B Sylvester, L Luput, A Sesarman, E Licarete, A Porfire, D Muntean, DM Drotar, AD Rusu, AL Nagy, C Catoi, I Tomuta, L Vlase, M Banciu, M Achim
Cancer biology & therapy 2017
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
U Amstutz, LM Henricks, SM Offer, J Barbarino, JH Schellens, JJ Swen, TE Klein, HL McLeod, KE Caudle, RB Diasio, M Schwab
Clinical Pharmacology & Therapeutics 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
M Boisdron-Celle, O Capitain, R Faroux, C Borg, JP Metges, MP Galais, M Kaassis, J Bennouna, K Bouhier-Leporrier, E Francois, I Baumgaertner, V Guerin-Meyer, O Cojocarasu, C Roemer-Becuwe, C Stampfli, L Rosenfeld, T Lecompte, V Berger, A Morel, E Gamelin
Seminars in Oncology 2017
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases: Genetic variability and treatment response
A DHAWAN, M RUWALI, MC PANT, Q RAHMAN, D PARMAR
Asia-Pacific Journal of Clinical Oncology 2016
Improving Safety of Fluoropyrimidine Chemotherapy by Individualizing Treatment Based on Dihydropyrimidine Dehydrogenase Activity – Ready for Clinical Practice?
D Meulendijks, A Cats, JH Beijnen, JH Schellens
Cancer Treatment Reviews 2016
5-Fluorouracil sensitivity varies among oral micro-organisms
TV de Wiele, B Vanhoecke, E Vanlancker, R Smet, R Props
Journal of Medical Microbiology 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid
M Yan, C Ho, E Winquist, D Jonker, D Rayson, L Stitt, S Tokmakejian, A Tomiak, MD Vincent
Clinical Colorectal Cancer 2016
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
D Bertholee, JG Maring, AB van Kuilenburg
Clinical Pharmacokinetics 2016
Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience
A Sahu, A Ramaswamy, V Ostwal
Journal of Gastrointestinal Oncology 2016
Inborn Metabolic Diseases
JM Saudubray, MR Baumgartner, J Walter
Inborn Metabolic Diseases 2016
Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population
T Elraiyah, CR Jerde, S Shrestha, R Wu, Q Nie, NH Giama, V Sarangi, LR Roberts, SM Offer, RB Diasio
Clinical Pharmacology & Therapeutics 2016
Pharmacogenetics of Cancer Drugs
DL Hertz, J Rae
Annual Review of Medicine 2015
Controlled delivery of hollow corn protein nanoparticles via non-toxic crosslinking: in vivo and drug loading study
H Xu, L Shen, L Xu, Y Yang
Biomedical Microdevices 2015
Genotype–phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction
G Gentile, A Botticelli, L Lionetto, F Mazzuca, M Simmaco, P Marchetti, M Borro
The Pharmacogenomics Journal 2015
Pharmacogenomics of fluorouracil-based chemotherapy toxicity
S Matsusaka, HJ Lenz
Expert Opinion on Drug Metabolism & Toxicology 2015
Principles of Translational Science in Medicine
AR van der Velde, WC Meijers, RA de Boer
Principles of Translational Science in Medicine 2015
Reviews in Cell Biology and Molecular Medicine
DL Hertz, HL McLeod
Reviews in Cell Biology and Molecular Medicine 2015
A systematic review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
AL Deac, CC Burz, HF Bocșe, IC Bocșan, AD Buzoianu
Medicine and pharmacy reports 2015
'Toxgnostics': an unmet need in cancer medicine
D Church, R Kerr, E Domingo, D Rosmarin, C Palles, K Maskell, I Tomlinson, D Kerr
Nature Reviews Cancer 2014
Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed
E Rivera, JC Chang, V Semiglazov, O Burdaeva, MG Kirby, T Spector
Clinical Breast Cancer 2014
La dihydropyrimidine déshydrogénase (DPD)
E Gamelin, M Boisdron-Celle, A Morel
Oncologie 2014
Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer
T Ochiai, M Umeki, H Miyake, T Iida, M Okumura, K Ohno, M Sakamoto, N Miyoshi, M Takahashi, H Tsumura, Y Tokunaga, H Naitou, T Fukui
Oncology reports 2014
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
LM Soveri, K Hermunen, A Gramont, T Poussa, E Quinaux, P Bono, T André, P Österlund
European Journal of Cancer 2014
DPYD Variants to Predict 5-FU Toxicity: The Ultimate Proof
F Innocenti
JNCI Journal of the National Cancer Institute 2014
Pharmacogenetic biomarkers for predicting drug response
PC Bank, JJ Swen, HJ Guchelaar
Expert Review of Molecular Diagnostics 2014
Guidance on the management of diarrhoea during cancer chemotherapy
J Andreyev, P Ross, C Donnellan, E Lennan, P Leonard, C Waters, L Wedlake, J Bridgewater, R Glynne-Jones, W Allum, I Chau, R Wilson, D Ferry
The Lancet Oncology 2014
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action
CL Kline, WS El-Deiry
Pharmaceuticals (Basel, Switzerland) 2013
A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity
SM Offer, AM Lee, LK Mattison, C Fossum, NJ Wegner, RB Diasio
Clinical Pharmacology & Therapeutics 2013
Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5-Fluorouracil-Based Chemotherapy Regimens
CL Kline, A Schiccitano, J Zhu, C Beachler, H Sheikh, HA Harvey, HB Mackley, K McKenna, K Staveley-O'Carroll, L Poritz, E Messaris, D Stewart, J Sivik, WS El-Deiry
Clinical Colorectal Cancer 2013
Emery and Rimoin's Principles and Practice of Medical Genetics
DC Wallace, MT Lott, V Procaccio
Emery and Rimoin's Principles and Practice of Medical Genetics 2013
Handbook of Therapeutic Biomarkers in Cancer
E Gross, A Kuilenburg
Handbook of Therapeutic Biomarkers in Cancer 2013
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients
AB van Kuilenburg, JG Maring
Pharmacogenomics 2013
Pharmacogenetics in dermatology: a patient-centered update
NI Comfere, ON Ikediobi, MS Peters, RA el-Azhary, LE Gibson
International Journal of Dermatology 2013
Genetics of Population Differences in Drug Response
M Bachtiar, CG Lee
Current Genetic Medicine Reports 2013
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
KE Caudle, CF Thorn, TE Klein, JJ Swen, HL McLeod, RB Diasio, M Schwab
Clinical Pharmacology & Therapeutics 2013
Detection of complete dihydropyrimidine dehydrogenase deficiency in a Tunisian family using a simple phenotypic test
A Mani, M Nouira, SB Ahmed, S Saguem
Indian journal of pharmacology 2013
Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China
X Zhang, B Sun, Z Lu
International journal of medical sciences 2013
Dihydropyrimidine dehydrogenase and fluoropyrimidines: a review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracil
M Boisdron-Celle, P Biason, E Gamelin, A Morel
Colorectal Cancer 2013
Indirect assessment of dihydropyrimidine dehydrogenase activity in cats: U:UH 2 in cats
CF Saba, CW Schmiedt, KG Freeman, GL Edwards
Veterinary and Comparative Oncology 2013
13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients
GF Cunha-Junior, L Marco, L Bastos-Rodrigues, MB Bolina, FL Martins, GA Pianetti, IC Cesar, LG Coelho
Cancer Chemotherapy and Pharmacology 2013
Médecine personnalisée en cancérologie digestive
O Bouché, P Laurent-Puig
2013
Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity
SM Offer, NJ Wegner, C Fossum, K Wang, RB Diasio
Cancer research 2013
A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Flurouracil in Patients With Gastrointestinal Cancer :
IC César, GF Cunha-Júnior, RM Byrro, LG Coelho, GA Pianetti
Therapeutic Drug Monitoring 2012
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a c.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy :
AB van Kuilenburg, P Häusler, A Schalhorn, MW Tanck, JH Proost, C Terborg, D Behnke, W Schwabe, K Jabschinsky, JG Maring
Clinical Pharmacokinetics 2012
Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis
MB Garg, LF Lincz, K Adler, FE Scorgie, SP Ackland, JA Sakoff
British Journal of Cancer 2012
A nanogel of on-site tunable pH-response for efficient anticancer drug delivery
T Zhou, C Xiao, J Fan, S Chen, J Shen, W Wu, S Zhou
Acta Biomaterialia 2012
Accidental and experimentally induced 5-fluorouracil toxicity in dogs: 5-Fluorouracil toxicity in dogs
RS Sayre, JW Barr, EM Bailey
Journal of Veterinary Emergency and Critical Care 2012
Metabolomics
RW Millard, PR Rosevear
Journal of the American College of Cardiology 2012
Cancer chemotherapy: A critical analysis of its 60 years of history
D Galmarini, CM Galmarini, FC Galmarini
Critical Reviews in Oncology/Hematology 2012
Let’s get personal: predicting thiopurine and fluoropyrimidine toxicity
A Corrigan, M Arenas-Hernandez, P Blaker, J Sanderson, A Marinaki
Personalized Medicine 2012
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
AB Kuilenburg, P Häusler, A Schalhorn, MW Tanck, JH Proost, C Terborg, D Behnke, W Schwabe, K Jabschinsky, JG Maring
Clinical Pharmacokinetics 2012
Biomarkers in Oncology
HJ Lenz
2012
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
AB van Kuilenburg, P Häusler, A Schalhorn, MW Tanck, JH Proost, C Terborg, D Behnke, W Schwabe, K Jabschinsky, JG Maring
Clinical Pharmacokinetics 2012
Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery
W Wu, J Shen, Z Gai, K Hong, P Banerjee, S Zhou
Biomaterials 2011
Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: A 5-year multicenter observational survey* :
GR Gristina, M Antonelli, G Conti, A Ciarlone, S Rogante, C Rossi, G Bertolini
Critical Care Medicine 2011
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli
Burger's Medicinal Chemistry and Drug Discovery 2010
Pharmaceutical Sciences Encyclopedia
D Farkas, RI Shader, LL von Moltke, DJ Greenblatt
Pharmaceutical Sciences Encyclopedia 2010
Cardiotoxicity of Non-Cardiovascular Drugs
FD Lisa, M Semenzato, A Carpi, S Menazza, N Kaludercic, R Menabò, M Canton
Cardiotoxicity of Non-Cardiovascular Drugs 2010
Selection of extreme phenotypes: the role of clinical observation in translational research
JL Pérez-Gracia, A Gúrpide, MG Ruiz-Ilundain, CA Alegría, R Colomer, J García-Foncillas, IM Bermejo
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2010
Insights into the mechanism of dihydropyrimidine dehydrogenase from site-directed mutagenesis targeting the active site loop and redox cofactor coordination
B Lohkamp, N Voevodskaya, Y Lindqvist, D Dobritzsch
Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 2010
Breath biomarkers for personalized medicine
AS Modak
Personalized Medicine 2010
Clinical significance of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma
M Tsuzuki, T Satomi, H Chiba
Oral Medicine & Pathology 2010
Dihydropyrimidine Dehydrogenase Deficiency Caused by a Novel Genomic Deletion c.505_513del ofDPYD
AB van Kuilenburg, J Meijer, G Gökcay, T Baykal, ME Rubio-Gozalbo, AN Mul, CE de Die-Smulders, P Weber, AC Mori, J Bierau, B Fowler, K Macke, JO Sass, R Meinsma, JB Hennermann, P Miny, L Zoetekouw, J Roelofsen, R Vijzelaar, J Nicolai, RC Hennekam
Nucleosides, Nucleotides and Nucleic Acids 2010
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study
A Tsunoda, K Nakao, M Watanabe, N Matsui, A Ooyama, M Kusano
Annals of Oncology 2010
Neurocatástrofes farmacológicas
CT García
Neurología 2010
The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients
MH Kristensen, P Pedersen, J Mejer
J INT MED RES 2010
Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients
MH Kristensen, PL Pedersen, GV Melsen, J Ellehauge, J Mejer
J INT MED RES 2010
Pharmacogenetics: Making cancer treatment safer and more effective
WG Newman
2010
Identification of genes conferring resistance to 5-fluorouracil
BK Yoo, R Gredler, N Vozhilla, Z Su, D Chen, T Forcier, K Shah, U Saxena, U Hansen, PB Fisher, D Sarkar
Proceedings of the National Academy of Sciences 2009
Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy
T Sakaeda, M Yamamori, A Kuwahara, K Nishiguchi
Advanced Drug Delivery Reviews 2009
Clinically available pharmacogenomics tests
DA Flockhart, T Skaar, DS Berlin, TE Klein, AT Nguyen
Clinical Pharmacology & Therapeutics 2009
Pharmacogenetics and pharmacogenomics of anticancer agents
RS Huang, MJ Ratain
CA: a cancer journal for clinicians 2009
13C-5-FU breath test current status and future directions: a comprehensive review
HH Ezzeldin, EP Acosta, LK Mattison, J Fourie, A Modak, RB Diasio
Journal of Breath Research 2009
Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment
S Shimoyama
Journal of Gastroenterology and Hepatology 2009
Pharmacogenetics: implementing personalized medicine
E Mini, S Nobili
Clinical Cases in Mineral and Bone Metabolism 2009
Pharmacology and Therapeutics
BL Clarke, S Khosla
Pharmacology & Therapeutics 2009
Toxicity and Efficacy of 5-Fluorouracil and Capecitabine in a Patient With TYMS Gene Polymorphism: A Challenge or a Dilemma?
A Shahrokni, MR Rajebi, MW Saif
Clinical Colorectal Cancer 2009
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics
HK Sanoff, HL McLeod
Seminars in colon & rectal surgery 2008
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1
K Fujita, W Yamamoto, S Endo, H Endo, F Nagashima, W Ichikawa, R Tanaka, T Miya, K Araki, K Kodama, Y Sunakawa, M Narabayashi, K Miwa, Y Ando, Y Akiyama, K Kawara, T Kamataki, Y Sasaki
Cancer Science 2008
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer
B Vincenzi, G Schiavon, F Pantano, D Santini, G Tonini
Nature Clinical Practice Oncology 2008
Cerebellar Toxicity with Capecitabine in a Patient with Metastatic Breast Cancer
M Mukesh, P Murray
Clinical Oncology 2008
Correlation between Clinical Pathologic Factors and Activity of 5-FU-Metabolizing Enzymes in Colorectal Cancer
T Yamada, N Tanaka, K Yokoi, T Seya, Y Kanazawa, M Koizumi, Y Ohaki, T Tajiri
Journal of Nippon Medical School 2008
Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene
AB van Kuilenburg, JG Maring, A Schalhorn, C Terborg, H Schmalenberg, D Behnke, W Schwabe, K Jabschinsky, P Hausler
Nucleosides, Nucleotides and Nucleic Acids 2008
Identification of Two Novel Mutations C79X and R235Q in the Dihydropyrimidine Dehydrogenase Gene in a Patient Presenting With Hematuria
AB van Kuilenburg, J Meijer, D Dobritzsch, B Lohkamp, W Ruitenbeek, J Roelofsen, NG Abeling, M Duran, C Buzing
Nucleosides, Nucleotides and Nucleic Acids 2008
Altered Dihydropyrimidine Dehydrogenase Activity Associated with Mild Toxicity in Patients Treated with 5-Fluorouracil Containing Chemotherapy
AB van Kuilenburg, HJ Klumpen, AM Westermann, L Zoetekouw, PJ Bakker, HJ Guchelaar, DJ Richel
Nucleosides, Nucleotides and Nucleic Acids 2008
Molecular Epidemiology: Applications in Cancer and Other Human Diseases
J Barnholtz-Sloan, I Halder, M Shriver
Molecular Epidemiology: Applications in Cancer and Other Human Diseases 2008
Surface-enhanced Raman Spectral Measurements of 5-Fluorouracil in Saliva
S Farquharson, A Gift, C Shende, F Inscore, B Ordway, C Farquharson, J Murren
Molecules (Basel, Switzerland) 2008
Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
M Schwab, UM Zanger, C Marx, E Schaeffeler, K Klein, J Dippon, R Kerb, J Blievernicht, J Fischer, U Hofmann, C Bokemeyer, M Eichelbaum
Journal of Clinical Oncology 2008
Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
E Gamelin, R Delva, J Jacob, Y Merrouche, JL Raoul, D Pezet, E Dorval, G Piot, A Morel, M Boisdron-Celle
Journal of Clinical Oncology 2008
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
F Innocenti
2008
HPLC with UV or Mass Spectrometric Detection for Quantifying Endogenous Uracil and Dihydrouracil in Human Plasma
R Švobaitė, I Solassol, F Pinguet, L Ivanauskas, J Brès, FM Bressolle
Clinical chemistry 2008
CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1
Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y
Cancer Science 2008
Targeted Therapies in Cancer
M Dietel
2007
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study
AA Garcia, JA Blessing, KM Darcy, HJ Lenz, W Zhang, E Hannigan, DH Moore
Gynecologic Oncology 2007
Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency
AB van Kuilenburg, J Meijer, D Dobritzsch, R Meinsma, M Duran, B Lohkamp, L Zoetekouw, NG Abeling, HL van Tinteren, AM Bosch
Molecular Genetics and Metabolism 2007
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin
AB van Kuilenburg, HJ Klumpen, AM Westermann, L Zoetekouw, HV Lenthe, PJ Bakker, DJ Richel, HJ Guchelaar
European Journal of Cancer 2007
Thymidylate Synthase (TYMS) and Dihydropyrimidine Dehydrogenase (DPYD) Polymorphisms in the Korean Population for Prediction of 5-Fluorouracil-Associated Toxicity
HJ Cho, YS Park, WK Kang, JW Kim, SY Lee
Therapeutic Drug Monitoring 2007
SSCP Screening of the Dihydropyrimidine Dehydrogenase Gene Polymorphisms of the Japanese Population Using a Semi-automated Electrophoresis Unit
Y Okamoto, A Ueta, S Sumi, T Ito, Y Okubo, Y Jose, A Ninomiya, H Togari, M Nishida
Biochemical Genetics 2007
Dépistage des patients déficitaires en dihydropyrimidine déhydrogénase avant traitement par fluoropyrimidines
E Gamelin, M Boisdron-Celle, A Morel
Thérapie 2007
Pour ou contre le phénotypage/génotypage des patients traités par le 5-fluorouracile pour prévenir les effets indésirables ?
R Coriat, S Chaussade
Thérapie 2007
Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area
SA Kaestner, GJ Sewell
Clinical Oncology 2007
5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency
M Boisdron-Celle, G Remaud, S Traore, AL Poirier, L Gamelin, A Morel, E Gamelin
Cancer Letters 2007
Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs
J Pander, H Gelderblom, HJ Guchelaar
Expert Opinion on Pharmacotherapy 2007
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007
JB (Moderator), MF (Moderator), JH Beumer, E Chu, A Paolo, C Eng, M Extermann, E Gamelin, H Hurwitz, G Milano, SJ Salamone, L Shaw
Clinical Colorectal Cancer 2007
Toxicity Profile and Efficacy of Oral Capecitabine as Adjuvant Chemotherapy for Chinese Patients with Stage III Colon Cancer
CC Law, YT Fu, KK Chau, TS Choy, PF So, KH Wong
Diseases of the Colon & Rectum 2007
Pharmacogénétique des anticancéreux
E Gamelin, M Boisdron-Celle, A Morel, O Capitain
Annales Pharmaceutiques Françaises 2007
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma
A Morel, M Boisdron-Celle, L Fey, P Lainé-Cessac, E Gamelin
Clinical Biochemistry 2007
Side Effects of Drugs Annual
T Vial, J Descotes, F Braun, M Behrend
Side Effects of Drugs Annual 2007
In Vivo Imaging of Cancer Therapy
AF Shields, P Price
2007
Ancestry and pharmacogenetics of antileukemic drug toxicity
S Kishi, C Cheng, D French, D Pei, S Das, EH Cook, N Hijiya, C Rizzari, GL Rosner, T Frudakis, CH Pui, WE Evans, MV Relling
Blood 2007
Pharmacogenetics of cancer chemotherapy
J Abraham, HM Earl, PD Pharoah, C Caldas
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2006
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy
AV Boddy
British Journal of Clinical Pharmacology 2006
Pharmacogenetics in the Management of Breast Cancer – Prospects for Individualised Treatment
FH Blackhall, S Howell, B Newman
Familial Cancer 2006
Dihydropyrimidindehydrogenase-Mangel und Fluorpyrimidin-Toxizität / Dihydropyrimidine dehydrogenase deficiency and fluoropyrimidine toxicity
M Steiner
LaboratoriumsMedizin 2006
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines
K Miyazaki, T Shibahara, D Sato, K Uchida, H Suzuki, H Matsui, A Yanaka, A Nakahara, Y Matsuzaki
Journal of Gastroenterology 2006
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy
T Ochiai, K Nishimura, H Noguchi, M Kitajima, A Tsukada, E Watanabe, I Nagaoka, S Futagawa
International Journal of Cancer 2006
How may Anticancer Chemotherapy with Fluorouracil be Individualised?
S Ploylearmsaeng, U Fuhr, A Jetter
Clinical Pharmacokinetics 2006
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
ML Maitland, K Vasisht, MJ Ratain
Trends in Pharmacological Sciences 2006
Dihydropyrimidine dehydrogenase deficiency in an Indian population
MW Saif, L Mattison, T Carollo, H Ezzeldin, RB Diasio
Cancer Chemotherapy and Pharmacology 2006
Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency
JH Baek, JG Kim, SN Kim, DH Kim, SK Sohn, YJ Hong, KB Lee
The Korean Journal of Internal Medicine 2006
Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine Therapy
C Mercier, J Ciccolini
Clinical Colorectal Cancer 2006
Capecitabine-Induced Cerebellar Toxicity
D Renouf, S Gill
Clinical Colorectal Cancer 2006
Hand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase–Deficient Patient Treated with Capecitabine
MW Saif, A Elfiky, R Diasio
Clinical Colorectal Cancer 2006
Colorectal Cancer
G Chong, D Cunningham
Colorectal Cancer 2006
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
SJ Gardiner, EJ Begg
Pharmacological reviews 2006
The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours
J Stoehlmacher
Annals of Oncology 2006
How may Anticancer Chemotherapy with Fluorouracil be Individualised?:
S Ploylearmsaeng, U Fuhr, A Jetter
Clinical Pharmacokinetics 2006
Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer:
TM Bosch, I Meijerman, JH Beijnen, JH Schellens
Clinical Pharmacokinetics 2006
Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics
R Soong, RB Diasio
Pharmacogenomics 2005
Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications
T Dervieux, B Meshkin, B Neri
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2005
Side effects during chemotherapy predict tumour response in advanced colorectal cancer
B Schuell, T Gruenberger, GV Kornek, N Dworan, D Depisch, F Lang, B Schneeweiss, W Scheithauer
British Journal of Cancer 2005
Does cisplatin (CDDP) function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial
S Matsusaka, T Nagareda, H Yamasaki
Cancer Chemotherapy and Pharmacology 2005
Analysis of 5-fluorouracil in saliva using surface-enhanced Raman spectroscopy
S Farquharson, C Shende, FE Inscore, P Maksymiuk, A Gift
Journal of Raman Spectroscopy 2005
Genetic factors influencing Pyrimidine-antagonist chemotherapy
JG Maring, HJ Groen, FM Wachters, DR Uges, EG de Vries
The Pharmacogenomics Journal 2005
Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function
AB van Kuilenburg, R Meinsma, E Beke, B Bobba, P Boffi, GM Enns, DR Witt, D Dobritzsch
Biological Chemistry 2005
Individualized chemotherapy based on genetic and genomic profiling
S Iqbal, HJ Lenz
Current Colorectal Cancer Reports 2005
Pharmacogenetics for individualized cancer chemotherapy
T Efferth, M Volm
Pharmacology & Therapeutics 2005
Detection of 5-fluorouracil in saliva using surface-enhanced Raman spectroscopy
S Farquharson, AD Gift, C Shende, P Maksymiuk, FE Inscore, J Murran
Vibrational Spectroscopy 2005
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice
F Innocenti, R Danesi, G Bocci, G Natale, MD Tacca
Toxicology and Applied Pharmacology 2005
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study
AA Garcia, JA Blessing, HJ Lenz, KM Darcy, RS Mannel, DS Miller, N Husseinzadeh
Gynecologic Oncology 2005
Sequence Analysis of the 5′-Flanking Regions of Human Dihydropyrimidine Dehydrogenase Gene: Identification of a New Polymorphism Related with Effects of 5-Fluorouracil
T Hasegawa, H Kim, M Fukushima, Y Wataya
Nucleosides, Nucleotides and Nucleic Acids 2005
Dihydropyrimidine déshydrogénase (DPD) : rythme et conséquences
MA Barrat-Petit, C Naulin-Ifi, P Mahler, G Milano
Pathologie Biologie 2005
Pharmacogénétique des médicaments anticancéreux
L Chaisemartin, MA Loriot
Pathologie Biologie 2005
NEUROTOXIC EFFECTS OF .ALPHA.-FLUORO-.BETA.-ALANINE (FBAL) AND FLUOROACETIC ACID (FA) ON DOGS
K YAMASHITA, H YADA
The Journal of Toxicological Sciences 2004
Thymidylate Synthase Expression in Normal Colonic Mucosa: A Predictive Marker of Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Adjuvant Chemotherapy
D Santini, B Vincenzi, G Perrone, C Rabitti, D Borzomati, M Caricato, AL Cesa, C Grilli, A Verzì, R Coppola, G Tonini
Oncology 2004
Using germ-line genetic variation to investigate and treat cancer
SA Savage, SJ Chanock
Drug Discovery Today 2004
Pyrimidine Degradation Defects and Severe 5‐Fluorouracil Toxicity
AB van Kuilenburg, R Meinsma, AH van Gennip
Nucleosides Nucleotides & Nucleic Acids 2004
CORRELATION BETWEEN CLINICAL PATHOPHYSIOLOGIC FEATURES AND EXPRESSION OF DIHYDROPYRIMIDINE DEHYDROGENASE (DPD), THYMIDYLATE SYNTHASE (TS), AND OROTATE PHOSPHORIBOSYL TRANSFERASE (OPRT) IN HEAD AND NECK CANCER
T ITO, S KOIKE, H KOSHU, T NASU, Y ABE, H INAMURA, M AOYAGI
Toukeibu Gan 2004
Primer on Medical Genomics: Part XII: Pharmacogenomics—General Principles With Cancer as a Model
MP Goetz, MM Ames, RM Weinshilboum
Mayo Clinic Proceedings 2004
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
AB van Kuilenburg
European Journal of Cancer 2004
Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms and Their Association with 5-Fluorouracil/Leucovorin Chemotherapy in Colorectal Cancer
AX Zhu, TA Puchalski, VP Stanton, DP Ryan, JW Clark, S Nesbitt, O Charlat, P Kelly, E Kreconus, BA Chabner, JG Supko
Clinical Colorectal Cancer 2004
Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil Administration
H Ezzeldin, R Diasio
Clinical Colorectal Cancer 2004
Tailored Chemotherapy for Colorectal Cancer: A New Approach to Therapy
S Iqbal, J Stoehlmacher, HJ Lenz
Cancer Investigation 2004
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
TA Rich, RC Shepard, ST Mosley
Journal of Clinical Oncology 2004
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
WD Figg, HL McLeod
2004
Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2- 13 C-Uracil Breath Test
LK Mattison, H Ezzeldin, M Carpenter, A Modak, MR Johnson, RB Diasio
Clinical cancer research 2004
Pharmacogenomics: marshalling the human genome to individualise drug therapy
WE Evans
Gut 2003
Molecular predictors of treatment and outcome in colorectal cancer
S Iqbal, HJ Lenz
Current Gastroenterology Reports 2003
Cancer pharmacogenomics: current and future applications
JW Watters, HL McLeod
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2003
Targeted therapy and pharmacogenomic programs
S Iqbal, HJ Lenz
Cancer 2003
Pharmacogenetic aspects in treatment of colorectal cancer – an update
J Stoehlmacher, E Goekkurt, HJ Lenz
Pharmacogenomics 2003
Inheritance and Drug Response
AE Guttmacher, FS Collins, R Weinshilboum
New England Journal of Medicine 2003
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma
Y Mizutani, H Wada, O Yoshida, M Fukushima, H Nakanishi, M Nakao, T Miki
European Journal of Cancer 2003
Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens:
JY Liu, W Zhou, AD Sferruzza, RA Bender
Anti-Cancer Drugs 2003
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil
NC Tebbutt, AR Norman, D Cunningham, M Allen, I Chau, J Oates, M Hill
British Journal of Cancer 2003
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889
M Endo, M Miwa, H Eda, M Ura, H Tanimura, T Ishikawa, T Miyazaki-Nose, K Hattori, N Shimma, H Yamada-Okabe, H Ishitsuka
International Journal of Cancer 2003
Intratumoural Thymidylate Synthase and Dihydropyrimidine Dehydrogenase Activities are Good Predictors of 5-Fluorouracil Sensitivity in Colorectal Cancer
Y Ishibiki, M Kitajima, K Sakamoto, Y Tomiki, S Sakamoto, T Kamano
J INT MED RES 2003
Implications of Genetic Testing in the Management of Colorectal Cancer:
J Stoehlmacher, HJ Lenz
American Journal of PharmacoGenomics 2003
Chemotherapy individualization
Gareth J Veal, Sally A Coulthard, Alan V Boddy
Investigational New Drugs 2003
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
JG Maring, AB van Kuilenburg, J Haasjes, H Piersma, HJ Groen, DR Uges, AH van Gennip, EG de Vries
British Journal of Cancer 2002
Candidate gene approach for pharmacogenetic studies
HZ Ring, DL Kroetz
Pharmacogenomics 2002
Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography–mass spectrometry
T Kuhara
Journal of Chromatography B 2002
Screening and diagnosis of ?-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine
M Ohse, M Matsuo, A Ishida, T Kuhara
Journal of Mass Spectrometry 2002
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics
LK Mattison, R Soong, RB Diasio
Pharmacogenomics 2002
The impact of pharmacogenomics on gastrointestinal cancer therapy
T Seufferlein, BO Boehm
Pharmacogenomics 2002
The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil
SJ Gardiner, EJ Begg, BA Robinson
Adverse Drug Reactions and Toxicological Reviews 2002
Dosing strategies for anticancer drugs: the good, the bad and body-surface area
A Felici, J Verweij, A Sparreboom
European Journal of Cancer 2002
Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil
Y Mizutani, H Nakanishi, O Yoshida, M Fukushima, B Bonavida, T Miki
European Journal of Cancer 2002
Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas
J Guillot
Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas 2002
The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research
JL Perez-Gracia, MG Ruiz-Ilundain, I Garcia-Ribas, EM Carrasco
Cancer 2002
Crystal Structure of the Productive Ternary Complex of Dihydropyrimidine Dehydrogenase with NADPH and 5-Iodouracil: IMPLICATIONS FOR MECHANISM OF INHIBITION AND ELECTRON TRANSFER
D Dobritzsch, S Ricagno, G Schneider, KD Schnackerz, Y Lindqvist
The Journal of biological chemistry 2002
Clinically Relevant Resistance in Cancer Chemotherapy
B Andersson, D Murray
2002
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
Sherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, Jordan D Berlin, Howard Bailey, Kim Binger, Jennifer Volkman, Dona Alberti, Chris Feierabend, Rebecca Marrocha, Rhoda Z Arzoomanian, George Wilding
Investigational New Drugs 2002
Determinants of prognosis and response to therapy in colorectal cancer
S Iqbal, HJ Lenz
Current Oncology Reports 2001
The clinical pharmacology of the oral fluoropyrimidines
CH Takimoto
Current Problems in Cancer 2001
PHARMACOGENOMICS: The Inherited Basis for Interindividual Differences in Drug Response
WE Evans, JA Johnson
Annual Review of Genomics and Human Genetics 2001
Cognitive Function and Reproductive Hormones in Adjuvant Therapy for Breast Cancer
CM Bender, KK Paraska, SM Sereika, CM Ryan, SL Berga
Journal of Pain and Symptom Management 2001
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer
Y Mizutani, H Wada, M Fukushima, O Yoshida, O Ukimura, A Kawauchi, T Miki
European Journal of Cancer 2001
Simple gas chromatographic–mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects
T Kuhara, C Ohdoi, M Ohse
Journal of Chromatography B: Biomedical Sciences and Applications 2001
High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity
R Déporte-Féty, M Picot, M Amiand, A Moreau, L Campion, D Lanoë, N Renée, G Milano
Journal of Chromatography B Biomedical Sciences and Applications 2001
Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil
MR Johnson, RB Diasio
Advances in Enzyme Regulation 2001
Pharmacogenetics and cancer therapy
MV Relling, T Dervieux
Nature Reviews Cancer 2001
Fluorouracil and the New Oral Fluorinated Pyrimidines
JG Kuhn
The Annals of pharmacotherapy 2001
Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer
JP Stevenson, M Redlinger, LA Kluijtmans, W Sun, K Algazy, B Giantonio, DG Haller, C Hardy, AS Whitehead, PJ ODwyer
Journal of Clinical Oncology 2001
Surgery
JA Norton, RR Bollinger, AE Chang, SF Lowry, SJ Mulvihill, HI Pass, RW Thompson
Surgery 2001
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells
N Takebe, SC Zhao, AU Ural, MR Johnson, D Banerjee, RB Diasio, JR Bertino
Cancer Gene Therapy 2001
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouraeil and folinic acid
A Wein, C Riedel, F Köckerling, P Martus, U Baum, WM Brueckl, T Reck, R Ott, J Hänsler, T Bernatik, D Becker, T Schneider, W Hohenberger, EG Hahn
Annals of Oncology 2001
Colorectal Cancer: A Clinical Guide to Therapy
H Bleiberg, N Kemeny, P Rougier, H Wilke
2001
The oral fluorinated pyrimidines
J S de Bono, C J Twelves
Investigational New Drugs 2001
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Habara K, Ajiki T, Kamigaki T, Nakamura T, Kuroda Y
Japanese journal of cancer research : Gann 2001
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group
A Ohtsu, H Baba, Y Sakata, Y Mitachi, N Horikoshi, K Sugimachi, T Taguchi
British Journal of Cancer 2000
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase
HL Kindler, RL Schilsky
Expert Opinion on Investigational Drugs 2000
Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action
A Saleem, J Yap, S Osman, F Brady, SV Lucas, T Jones, PM Price, EO Aboagye
The Lancet 2000
In-vivo Drug Delivery of 5-Fluorouracil using Poly(2-hydroxyethyl methacrylate-co-acrylamide) Hydrogels
MD Blanco, O GARCIA, C GOMEZ, RL Sastre, JM Teijon
Journal of Pharmacy and Pharmacology 2000
Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil
SD Baker, RB Diasio, S OReilly, VS Lucas, SP Khor, SE Sartorius, RC Donehower, LB Grochow, T Spector, JA Hohneker, EK Rowinsky
Journal of Clinical Oncology 2000
Monogen bedingte Erbkrankheiten 1
D Ganten, K Ruckpaul
2000
Pharmacogenetics: A Tool for Individualising Antineoplastic Therapy
F Innocenti, L Iyer, MJ Ratain
Clinical Pharmacokinetics 2000
Pharmacology of fluorinated pyrimidines: eniluracil
S D Baker
Investigational New Drugs 2000
Therapeutic drug monitoring of antimetabolic cytotoxic drugs
L Lennard
British Journal of Clinical Pharmacology 1999
5-Fluorouracil toxicity
BJ Kennedy
Cancer 1999
Dihydropyrimidine Dehydrogenase Activity in a Korean Population
DR Sohn, MS Cho, PJ Chung
Therapeutic Drug Monitoring 1999
5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy
L lyer, MJ Ratain
Cancer Investigation 1999
Prolonged Severe 5-Fluorouracil-Associated Neurotoxicity in a Patient with Dihydropyrimidine Dehydrogenase Deficiency
N Shehata, A Pater, SC Tang
Cancer Investigation 1999
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer—status of the art
E Gamelin, M Boisdron-Celle
Critical Reviews in Oncology/Hematology 1999
Automated determination of 5-fluorouracil and its metabolite in urine by high-performance liquid chromatography with column switching
T Maeda, S Sumi, K Hayashi, K Kidouchi, T Owaki, H Togari, S Fujimoto, Y Wada
Journal of Chromatography B Biomedical Sciences and Applications 1999
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
G Milano, MC Etienne, V Pierrefite, M Barberi-Heyob, R Deporte-Fety, N Renée
British Journal of Cancer 1999
Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage
E Gamelin, M Boisdron-Celle, V Guérin-Meyer, R Delva, A Lortholary, F Genevieve, F Larra, N Ifrah, J Robert
Journal of Clinical Oncology 1999
Neutropenia following Perioperative Intraperitoneal Chemotherapy
KJ Schnake, PH Sugarbaker, D Yoo
TUMORI 1999
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients
AB Kuilenburg, H van Lenthe, MJ Blom, EP Mul, AH Gennip
British Journal of Cancer 1999
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
WE Evans, MV Relling
Science 1999
Cardiotoxicity of the Antiproliferative Compound Fluorouracil:
K Becker, JF Erckenbrecht, D Haussinger, T Frieling
Drugs 1999
Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase
RB Diasio
British Journal of Clinical Pharmacology 1998
Pharmacogenetics of cancer therapy: getting personal
EY Krynetski, WE Evans
The American Journal of Human Genetics 1998
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
SA Ridge, J Sludden, X Wei, A Sapone, O Brown, S Hardy, P Canney, P Fernandez-Salguero, FJ Gonzalez, J Cassidy, HL McLeod
British Journal of Cancer 1998
Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy
P Canal, E Gamelin, G Vassal, J Robert
Pathology & Oncology Research 1998
Neurological complications of 5-fluorouracil chemotherapy: Case report and review of the literature
HA Bygrave, JI Geh, Y Jani, R Glynne-Jones
Clinical Oncology 1998
Pharmacogenetics and cancer chemotherapy
L Iyer, MJ Ratain
European Journal of Cancer 1998
5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply
KH Yeh, AL Cheng
British Journal of Cancer 1998
Purine and Pyrimidine Metabolism in Man IX
A Griesmacher, MM Müller, P Chiba
1998
High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy
KH Yeh, AL Cheng
British Journal of Cancer 1997
Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity
AV Kuilenburg
European Journal of Cancer 1997
Subcellular Localization of Dihydropyrimidine Dehydrogenase
AB van Kuilenburg, HV Lenthe, RJ Wanders, AH van Gennip
Biological Chemistry 1997
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster*
J Yan, SK Tyring, MM McCrary, PC Lee, S Haworth, R Raymond, SJ Olsen, RB Diasio
Clinical Pharmacology & Therapeutics 1997
A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites
E Gamelin, M Boisdron-Celle, F Larra, J Robert
Journal of Liquid Chromatography & Related Technologies 1997
EXPERIMENTAL CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF COLORECTAL CARCINOMA
S O'Reilly, EK Rowinsky
Hematology/Oncology Clinics of North America 1997
Simultaneous Determination of Dihydrofluorouracil and 5-Fluorouracil in Plasma by High-Performance Liquid Chromatography
SP Ackland, MB Garg, RH Dunstan
Analytical Biochemistry 1997
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity
MR Johnson, J Yan, L Shao, N Albin, RB Diasio
Journal of Chromatography B: Biomedical Sciences and Applications 1997
Common cancers—Immunotherapy and multidisciplinary therapy: Parts III and IV
WD Quan, CS Palackdharry
Disease-a-Month 1997
Mechanisms of Action and modulation of fluorouracil
JL Grem
Seminars in radiation oncology 1997
Inborn errors of pyrimidine degradation: Clinical, biochemical and molecular aspects
AH van Gennip, NG Abeling, P Vreken, AB van Kuilenburg
Journal of Inherited Metabolic Disease 1997
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero
Journal of Clinical Investigation 1996
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
P Vreken, AB Kuilenburg, R Meinsma, GP Smit, HD Bakker, RA Abreu, AH Gennip
Journal of Inherited Metabolic Disease 1996
Individualizing Therapy with 5-Fluorouracil Related to Dihydropyrimidine Dehydrogenase: Theory and Limits
G Milano, MC Etienne
Therapeutic Drug Monitoring 1996
Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity
T Tateishi, H Nakura, M Watanabe, M Tanaka, T Kumai, S Kobayashi
Clinica Chimica Acta 1996
Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole: The use of thallium SPECT imaging to assist in noninvasive diagnosis--A case report
DM Savarese, J Gordon, TW Smith, NS Litofsky, R Licho, R Ragland, L Recht
Cancer 1996
The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists
T Tateishi, H Nakura, M Watanabe, M Tanaka, T Kumai, S Kobayashi
Cancer Letters 1996
Pyrimidines and CNS regulation
GP Connolly, HA Simmonds, JA Dulay
Trends in Pharmacological Sciences 1996
Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine*
R Peck, R Wiggs, J Callaghan, R Wootton, P Crome, I Fraser, L Frick, J Posner
Clinical Pharmacology & Therapeutics 1996
cDNA cloning of bovine liver dihydropyrimidine dehydrogenase
N Albin, MR Johnson, RB Diasio
Mitochondrial DNA 1996
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta
P Beuzeboc, JY Pierga, D Stoppa-Lyonnet, MC Etienne, G Milano, P Fouillait
European Journal of Cancer 1996
Monoclonal Antibodies in Cancer Therapy: New Perspectives After the Colorectal Carcinoma Trial
E Holz, R Gruber, G Riethmüller
Clinical immunotherapeutics 1996
Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical development
GJ Peters, SP Ackland
Expert Opinion on Investigational Drugs 1996
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
P Vreken, AB Kuilenburg, R Meinsma, GP Smit, HD Bakker, RA Abreu, AH van Gennip
Journal of Inherited Metabolic Disease 1996
Chronobiology Implications for cancer chemotherapy
GA Bjarnason
Acta Oncologica 1995
Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes
P Fernandez-Salguero
Biochemical Pharmacology 1995
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*
Z Lu, R Zhang, RB Diasio
Clinical Pharmacology & Therapeutics 1995
Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uracilurea
R Meinsma, P Fernandez-Salguero, AV Kuilenburg, AV Gennip, F Gonzalez
DNA and Cell Biology 1995
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities
F Stéphan, MC Etienne, C Wallays, G Milano, F Clergue
The American Journal of Medicine 1995
Role of the Lung in Accumulation and Metabolism of Xenobiotic Compounds — Implications for Chemically Induced Toxicity
H Foth
Critical Reviews in Toxicology 1995
Combined deficiencies of NADPH- and NADH-dependent dihydropyrimidine dehydrogenases, a new finding in a family with thymine-uraciluria
AH van Gennip, H van Lenthe, NG Abeling, HD Bakker, AB van Kuilenburg
Journal of Inherited Metabolic Disease 1995
Concepts, Mechanisms, and New Targets for Chemotherapy
FM Muggia
1995
Individual dose adaptation of anticancer drugs
B Desoize, J Robert
European Journal of Cancer 1994
Évolution de la pharmacocinétique à la pharmacogénétique. L'exemple du 5-fluorouracile
G Milano, MC Étienne
La Revue de Médecine Interne 1994
Purine and Pyrimidine Metabolism in Man VIII
A Sahota, MW Taylor
1994
Plasma 5-fluorouracil and ?-fluoro-?-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil
L Thiberville, P Compagnon, N Moore, G Bastian, MO Richard, MF Hellot, C Vincent, MM Kannass, S Dominique, C Thuillez, G Nouvet
Cancer Chemotherapy and Pharmacology 1994
Cancer Treatment An Update
P Banzet, JF Holland, D Khayat, M Weil
1994
Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine
HJ Keizer, EA Bruijn, UR Tjaden, ED Clercq
Journal of Cancer Research and Clinical Oncology 1994
cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
H Yokota, P Fernandez-Salguero, H Furuya, K Lin, OW McBride, B Podschun, KD Schnackerz, FJ Gonzalez
The Journal of biological chemistry 1994
Pharmacogenetic Phenotyping and Genotyping: Present Status and Future Potential
FJ Gonzalez, JR Idle
Clinical Pharmacokinetics 1994
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
DP Baccanari, ST Davis, VC Knick, T Spector
Proceedings of the National Academy of Sciences 1993
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions
R Mick, MJ Ratain
Cancer Chemotherapy and Pharmacology 1993
The effect of dietary protein depletion on hepatic 5-Fluorouracil metabolism
LE Davis, RE Lenkinski, MA Shinkwin, HY Kressel, JM Daly
Cancer 1993
Severe 5-Fluorouracil Toxicity in a Patient with Decreased Dihydropyrimidine Dehydrogenase Activity
AP Lyss, RC Lilenbaum, BE Harris, RB Diasio
Cancer Investigation 1993
Identity of D-3-aminoisobutyrate-pyruvate aminotransferase with alanine-glyoxylate aminotransferase 2
Y Kontani, M Kaneko, M Kikugawa, S Fujimoto, N Tamaki
Biochimica et Biophysica Acta (BBA) - General Subjects 1993
Dihydropyrimidine dehydrogenase activity in cancer patients
GA Milano, MH Gaspard, A Thyss, N Renée, M Schneider, F Demard, RA Fleming, PJ Bargnoux, R Plagne
European Journal of Cancer 1993
The Role of Pharmacogenetics in Cancer Chemotherapy and the Development of Malignancy
RJ Irvin, JG Kuhn
Journal of Pharmacy Practice 1993
Acid-base catalytic mechanism of dihydropyrimidinase from pH studies
K Jahnke, B Podschun, KD Schnackerz, J Kautz, PF Cook
Biochemistry 1993
Molecular Genetics, Biochemistry and Clinical Aspects of Inherited Disorders of Purine and Pyrimidine Metabolism
U Gresser
1993
Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients
GA Bjarnason, IG Kerr, N Doyle, M Macdonald, M Sone
Cancer Chemotherapy and Pharmacology 1993
Purification and characterization of dihydropyrimidine dehydrogenase from human liver
ZH Lu, R Zhang, RB Diasio
The Journal of biological chemistry 1992
Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism
M Duran, P Rovers, PK Bree, CH Schreuder, H Beukenhorst, L Dorland, R Berger
Journal of Inherited Metabolic Disease 1991
The Multifrequency (Circadian, Fertility Cycle, and Season) Balance between Host and Cancer
WJ Hrushesky
Annals of the New York Academy of Sciences 1991
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome
BE Harris, JT Carpenter, RB Diasio
Cancer 1991
Oxidation of 5-Bromo- and 5-Fluoro-1,3-dimethyluracils by Peroxomono- and Peroxodisulfate Ions
T Itahara, A Nishino
Chemistry Letters 1991
Biochemical Basis for Circadian-Dependent Metabolism of Fluoropyrimidines
GC Daher, BE Harris, EM Willard, RB Diasio
Annals of the New York Academy of Sciences 1991
Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil
GC Daher, FN Naguib, MH el Kouni, R Zhano, SJ Soong, RB Diasio
Biochemical Pharmacology 1991
Purine and Pyrimidine Metabolism in Man VII
RA Harkness, GB Elion, N Zöllner
1991
A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients
C Coustre, F Mentr, JP Sommadossi, RB Diasio, JL Steimer
Cancer Chemotherapy and Pharmacology 1991
Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil
DJ Porter, WG Chestnut, LC Taylor, BM Merrill, T Spector
The Journal of biological chemistry 1991
Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism
M Duran, P Rovers, PK de Bree, CH Schreuder, H Beukenhorst, L Dorland, R Berger
Journal of Inherited Metabolic Disease 1991
Metabolism of pyrimidine analogues and their nucleosides
GC Daher, BE Harris, RB Diasio
Pharmacology & Therapeutics 1990
A new case of dihydropyrimidine dehydrogenase deficiency
M Brockstedt, C Jakobs, LM Smit, AH Gennip, R Berger
Journal of Inherited Metabolic Disease 1990
5-Fluorouracil neurotoxicity
DH Moore, WC Fowler, LS Crumpler
Gynecologic Oncology 1990
Dihydropyrimidinuria
M Duran, P Rovers, PK Bree, CH Schreuder, H Beukenhorst, L Dorland, R Berger
The Lancet 1990
Neurological Adverse Reactions to Anticancer Drugs
J Hildebrand
1990
A new case of dihydropyrimidine dehydrogenase deficiency
M Brockstedt, C Jakobs, LM Smit, AH van Gennip, R Berger
Journal of Inherited Metabolic Disease 1990
Purification and properties of 5,6-dihydropyrimidine amidohydrolase from calf liver
J KAUTZ, KD SCHNACKERZ
European Journal of Biochemistry 1989
Clinical Pharmacology of 5-Fluorouracil:
RB Diasio, BE Harris
Clinical Pharmacokinetics 1989
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase
BE Harris, R Song, YJ He, SJ Soong, RB Diasio
Biochemical Pharmacology 1988
Pharmacogenetics
BM Watson
Anaesthesia 1969

← Previous 1 2 3 … 14 15 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 31 news outlets
Blogged by 3
Referenced in 1 policy sources
Referenced in 2 patents
Referenced in 2 Wikipedia pages
Referenced in 1 clinical guideline sources
83 readers on Mendeley
See more details